1. Search Result
Search Result
Results for "

glucose uptake

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

3

Peptides

14

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N5083
    Saponarin
    1 Publications Verification

    Others Inflammation/Immunology
    Saponarin is a natural flavonoid isolated from Gypsophila trichotoma, with antioxidant, anti-inflammatory and hepatoprotective activities. Saponarin activates AMPK in a calcium-dependent manner, thus regulating gluconeogenesis and glucose uptake .
    Saponarin
  • HY-N7605

    Others Metabolic Disease
    11-epi-mogroside V is a mogroside in the fruit of Siraitia grosvenori. 11-epi-mogroside V exhibits considerable bioactivity in promoting glucose uptake in human HepG2 cells in vitro .
    11-epi-mogroside V
  • HY-113870

    Fluorescent Dye Others
    6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .
    6-NBDG
  • HY-N8490

    Others Metabolic Disease
    Eicosyl ferulate, a phenolic compound, is isolated from the fresh root and stem of Aristolochia kankauensis. Eicosyl ferulate exhibits glucose uptake stimulatory activity .
    Eicosyl ferulate
  • HY-W411439

    Others Metabolic Disease
    1-O-p-Coumaroyl-β-D-glucose can promote glucose uptake in HuH7 cells, and be be extracted from Luffa cylindrica (L.) Roem (sponge gourds) .
    1-O-p-Coumaroyl-β-D-glucose
  • HY-146036

    Endogenous Metabolite Metabolic Disease
    NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes .
    NADH-IN-1
  • HY-163294

    PPAR Metabolic Disease
    PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .
    PPARγ agonist 10
  • HY-153018

    Phosphatase Metabolic Disease
    PTP1B-IN-22, a ZINC02765569 derivative, is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor. PTP1B-IN-22 has PTP1B inhibition and glucose uptake in skeletal muscle L6 myotubes .
    PTP1B-IN-22
  • HY-142088

    Endogenous Metabolite Metabolic Disease
    Beauverolide Ka, a cyclotetradepsipeptide, is a metabolite of Beauveria bassiana fungus. Beauverolide Ka stimulates glucose uptake in cultured rat L6 myoblasts at 50 μM. Beauverolide Ka exhibits protecting effects on HEI-OC1 cells at 10 μM and shows dose-dependent activity in both L6 myoblasts and myotubes .
    Beauverolide Ka
  • HY-W040127

    Insulin Receptor Metabolic Disease
    Peonidin 3-O-glucoside chloride, an anthocyanin, act as an insulin secretagogue. Peonidin 3-O-glucoside chloride can increase glucose uptake in HepG2 cells. Peonidin 3-O-glucoside chloride has the potential for type-2 diabetes comorbidities research .
    Peonidin 3-O-glucoside chloride
  • HY-103721

    Sirtuin Cancer
    SIRT6-IN-2 (Compound 5) is a selective SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .
    SIRT6-IN-2
  • HY-N3426

    NO Synthase Akt AMPK Metabolic Disease
    Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .
    Kazinol B
  • HY-W176629

    E1/E2/E3 Enzyme Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research .
    Hydrocotarnine
  • HY-N0457
    Chicoric acid
    1 Publications Verification

    Cichoric acid; Dicaffeoyltartaric acid

    Reactive Oxygen Species Apoptosis Metabolic Disease Inflammation/Immunology
    Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
    Chicoric acid
  • HY-N8438

    Methyl lignocerate; Tetracosanoic Acid Methyl Ester

    Others Metabolic Disease
    Methyl tetracosanoate (Methyl lignocerate) is a fatty acid methyl ester with anti-diabetic activity .
    Methyl tetracosanoate
  • HY-101903
    BMS-309403
    10+ Cited Publications

    FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403
  • HY-101903A
    BMS-309403 sodium
    10+ Cited Publications

    FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403 sodium
  • HY-153612

    GLUT Parasite Infection Inflammation/Immunology
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
    MMV009085
  • HY-139409

    Others Metabolic Disease
    2-Deoxy-D-glucose 6-phosphate is an intermediate of 2-deoxy-D-glucose (2-DG) . 2-Deoxy-D-glucose is incorporated into glycogen .
    2-Deoxy-D-glucose 6-phosphate
  • HY-N7912

    (2S)-Pterosin A

    Others Metabolic Disease
    Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .
    Pterosin A
  • HY-N2486
    Desoxyrhaponticin
    1 Publications Verification

    Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
    Desoxyrhaponticin
  • HY-156690

    Others Metabolic Disease
    2-Quinizarincarboxylic acid (Compound 15) is a glucose uptake inhibitor, with the inhibitory rate of 24.9% at 50 μM .
    2-Quinizarincarboxylic acid
  • HY-124417

    Others Metabolic Disease
    SBI-477 (compound 41) analog inhibits intracellular lipid accumulation, increase celluar glucose uptake .
    SBI-477 analog
  • HY-18728
    STF-31
    5+ Cited Publications

    GLUT Autophagy Cancer
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .
    STF-31
  • HY-N2209

    Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ .
    Angeloylgomisin H
  • HY-N1185

    Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .
    Tagitinin A
  • HY-101849
    Fasentin
    4 Publications Verification

    GLUT TNF Receptor Apoptosis Cardiovascular Disease Cancer
    Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
    Fasentin
  • HY-155961

    Dipeptidyl Peptidase Phosphatase Amylases Glucosidase Metabolic Disease
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .
    Antidiabetic agent 2
  • HY-163279

    Others Others
    Fluopipamine is an antagonist for Cellulose Synthase 1 (CESA1) with an IC50 of 0.78 μM. Fluopipamine leads a decrease in glucose uptake into cellulose and hyperaccumulation of CESAs at the PM in etiolated Arabidopsis seedlings .
    Fluopipamine
  • HY-P1473

    Amylin (8-37) (mouse, rat)

    Amylin Receptor Metabolic Disease
    Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
    Amylin (8-37), rat
  • HY-N6258

    AMPK Apoptosis Metabolic Disease
    Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
    Kahweol
  • HY-130319A

    PPAR Cardiovascular Disease Metabolic Disease
    9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
    9-HEPE
  • HY-18686

    AS1949490 is a potent, orally active, selective SHIP2 phosphatase inhibitor with IC50 values of 0.34, 0.62, 13, >50, >50, and >50 µM for Mouse SHIP2, Human SHIP2, Human SHIP1, Human PTEN, Human synaptojanin, and Human myotubularin, respectively. AS1949490 increases the phosphorylation of Akt, glucose consumption and glucose uptake. AS1949490 activates intracellular insulin signalling pathways. AS1949490 can be used for research of diabetes .
    AS1949490
  • HY-149727

    Adrenergic Receptor Metabolic Disease
    β2AR agonist 2(compound 8a) is a β2 -Adrenergic receptor (β2AR) agonist. β2AR agonist 2 is a saturated nitrogen ring compound containing 4- to 7-membered heterocycle. β2AR agonist 2 has a chiral structure (the -R form) by carrying carbon containing the essential hydroxyl, thereby enhancing cellular glucose uptake (GU) activity and significantly stimulating glucose uptake by skeletal muscle cells. β2AR agonist 2 can be used in the study of Type 2 Diabetes (T2D) .
    β2AR agonist 2
  • HY-N7676

    AMPK HDAC Cardiovascular Disease Neurological Disease Metabolic Disease
    Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .
    Marein
  • HY-B1080A
    Tilorone
    1 Publications Verification

    Influenza Virus Akt Infection Metabolic Disease Inflammation/Immunology Cancer
    Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .
    Tilorone
  • HY-118567

    BMOV

    SHP2 Phosphatase Metabolic Disease
    Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer .
    Bis(maltolato)oxovanadium(IV)
  • HY-P2048A

    AMPK GLUT Metabolic Disease
    MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity .
    MOTS-c(human) acetate
  • HY-19824
    3PO
    15+ Cited Publications

    Autophagy Cancer
    3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD + and NADH. 3PO can be used for the research of cancer .
    3PO
  • HY-124418

    Others Metabolic Disease
    SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes .
    SBI-477
  • HY-123194

    Histone Demethylase Sirtuin Metabolic Disease
    SIRT2/6-IN-1 (Compound 5) is a SIRT6/SIRT2 inhibitor, with IC50s of 106 μM and 114 μM. SIRT2/6-IN-1 increases H3K9 acetylation, increases glucose uptake and reduces TNF-α secretion in cells .
    SIRT2/6-IN-1
  • HY-12203
    PFK-158
    5+ Cited Publications

    Autophagy Apoptosis Cancer
    PFK-158 is a potent and selective PFKFB3 inhibitor with an IC50 value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria .
    PFK-158
  • HY-148114

    Others Cancer
    MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP (HY-148114). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggers methuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells .
    MOPIPP
  • HY-143260

    GSK-3 Metabolic Disease Inflammation/Immunology Cancer
    GSK-3β inhibitor 6 is a potent GSK-3β inhibitor with an IC50 value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .
    GSK-3β inhibitor 6
  • HY-D0090
    MQAE
    5+ Cited Publications

    Fluorescent Dye Others
    MQAE is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. MQAE can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes.
    MQAE
  • HY-N1511
    Ganoderic acid D
    1 Publications Verification

    Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .
    Ganoderic acid D
  • HY-13991A

    Ras Metabolic Disease Cancer
    (S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes .
    (S)-CCG-1423
  • HY-116215
    2-NBDG
    Maximum Cited Publications
    27 Publications Verification

    Fluorescent Dye Others
    2-NBDG is a fluorescently-labeled deoxyglucose analog that is used primarily to directly monitor glucose uptake by living cells and tissues. It is also used as a topical contrast reagent for the detection of neoplasia. 2-NBDG can be used in real-time confocal, high-resolution, or wide-field fluorescence microscopy as well as in flow cytometry. The probe can be excited by the Argon laser at 488 nm to give the environment-sensitive fluorescence. It has lower photostability than the rhodamine-based fluorescent probes.
    2-NBDG
  • HY-115461

    Insulin Receptor Metabolic Disease
    MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake .
    MID-1
  • HY-132898

    PI3K Others
    PI3K-IN-23 is an (E)-9-oxooctadec-10-en-12-ynoic acid analogue to promote glucose uptake with an EC50 value of 7.00 μM. PI3K-IN-23 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PI3K-IN-23

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: